Coramaze Technologies

About

Headcount over time

Offices

Q&A

What is Coramaze Technologies' primary focus?

Coramaze Technologies develops minimally invasive medical devices and catheter systems for treating structural heart conditions, specifically targeting tricuspid and mitral regurgitation.

Where is Coramaze Technologies headquartered and where does it have an R&D center?

Coramaze Technologies is headquartered in Germany and has a dedicated R&D center in Petah Tikva, Israel.

What is the total amount of funding Coramaze Technologies has raised to date?

Coramaze Technologies has raised a total of $6,510,000 USD.

When did Coramaze Technologies raise its Seed round and who were the lead investors?

In February 2014, Coramaze Technologies raised a Seed round with lead investors.

When did Coramaze Technologies complete its Series A funding round and who was the lead investor?

Coramaze Technologies completed its Series A funding round in September 2015, with Elron Electronic Industries as the lead investor.

What is Coramaze Technologies' current employee count?

Coramaze Technologies has an employee count in the 11-50 range.

What is the product stage of Coramaze Technologies' offerings?

Coramaze Technologies' products are currently in the clinical trial stage.

What is the name of Coramaze Technologies' device for tricuspid valve disease?

Coramaze Technologies develops the Tripair device for the percutaneous treatment of tricuspid valve disease.

Team · 11

Laura Figulla

Founder · Co-founder & CEO

Till Neumann

Founder · Inventor, CSO / Managing Director

Rob ten Hoedt

Board Chair

Jochen Reinöhl

CEO

Grayston Licht

Chief Medical Officer

Laurie Hayner

CTO

Jacob van Dam

VP Clinical Operations

Konstantin Winterhalder

Director of Quality Assurance

Claude Herskovits

Board Director

Christoph Kausch

Board Director

Erich Platzer

Board Director

Sectors & technology

Highlights

Tags